GSK’s Promacta Gets ODAC Nod Despite Concerns Of Off-Label, Long-Term Use

Despite concerns over off-label use of GlaxoSmithKline's Promacta, FDA's Oncologic Drugs Advisory Committee unanimously backed the drug for short-term use, voting 16-0 that the clinical data demonstrate a favorable risk-benefit ratio